208 related articles for article (PubMed ID: 33676945)
1. Serum microRNAs and antifibrotic response to eplerenone in acute myocardial infarction complicated by systolic dysfunction.
Stienen S; Ferreira JP; Bär C; Thum T; Barros A; Pitt B; Girerd N; Rossignol P; Zannad F
Int J Cardiol; 2021 Jun; 332():35-37. PubMed ID: 33676945
[TBL] [Abstract][Full Text] [Related]
2. Determinants of anti-fibrotic response to mineralocorticoid receptor antagonist therapy: insights from the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS) and Early Eplerenone Treatment in Patients with Acute ST-elevation Myocardial Infarction without Heart Failure (REMINDER) trials.
Stienen S; Rossignol P; Barros A; Girerd N; Pitt B; Zannad F; Ferreira JP
Clin Res Cardiol; 2020 Feb; 109(2):194-204. PubMed ID: 31250134
[TBL] [Abstract][Full Text] [Related]
3. Extracellular cardiac matrix biomarkers in patients with acute myocardial infarction complicated by left ventricular dysfunction and heart failure: insights from the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS) study.
Iraqi W; Rossignol P; Angioi M; Fay R; Nuée J; Ketelslegers JM; Vincent J; Pitt B; Zannad F
Circulation; 2009 May; 119(18):2471-9. PubMed ID: 19398668
[TBL] [Abstract][Full Text] [Related]
4. Effect of eplerenone on extracellular cardiac matrix biomarkers in patients with acute ST-elevation myocardial infarction without heart failure: insights from the randomized double-blind REMINDER Study.
Ferreira JP; Duarte K; Montalescot G; Pitt B; de Sa EL; Hamm CW; Flather M; Verheugt F; Shi H; Turgonyi E; Orri M; Rossignol P; Vincent J; Zannad F
Clin Res Cardiol; 2018 Jan; 107(1):49-59. PubMed ID: 28852839
[TBL] [Abstract][Full Text] [Related]
5. Effects of mineralocorticoid receptor antagonist eplerenone on cardiac sympathetic nerve activity and left ventricular remodeling after reperfusion therapy in patients with first ST-segment elevation myocardial infarction.
Toda K; Kasama S; Toyama T; Kasahara M; Kurabayashi M
J Nucl Cardiol; 2022 Oct; 29(5):2325-2335. PubMed ID: 34272676
[TBL] [Abstract][Full Text] [Related]
6. Cost effectiveness of eplerenone in patients with heart failure after acute myocardial infarction who were taking both ACE inhibitors and beta-blockers: subanalysis of the EPHESUS.
Zhang Z; Mahoney EM; Kolm P; Spertus J; Caro J; Willke R; Weintraub WS
Am J Cardiovasc Drugs; 2010; 10(1):55-63. PubMed ID: 20104935
[TBL] [Abstract][Full Text] [Related]
7. Serum potassium and clinical outcomes in the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS).
Pitt B; Bakris G; Ruilope LM; DiCarlo L; Mukherjee R;
Circulation; 2008 Oct; 118(16):1643-50. PubMed ID: 18824643
[TBL] [Abstract][Full Text] [Related]
8. The association between markers of type I collagen synthesis and echocardiographic response to spironolactone in patients at risk of heart failure: findings from the HOMAGE trial.
Kobayashi M; Girerd N; Ferreira JP; Kevin D; Huttin O; González A; Bozec E; Clark AL; Cosmi F; Cuthbert J; Diez J; Edelmann F; Hazebroek M; Heymans S; Mariottoni B; Pellicori P; Petutschnigg J; Pieske B; Staessen JA; Verdonschot JAJ; Rossignol P; Cleland JGF; Zannad F
Eur J Heart Fail; 2022 Sep; 24(9):1559-1568. PubMed ID: 35703355
[TBL] [Abstract][Full Text] [Related]
9. Heart failure with systolic dysfunction complicating acute myocardial infarction - differential outcomes but similar eplerenone efficacy by ST-segment or non-ST-segment elevation: A post hoc substudy of the EPHESUS trial.
Carillo S; Zhang Y; Fay R; Angioi M; Vincent J; Sutradhor SC; Ahmed A; Pitt B; Zannad F
Arch Cardiovasc Dis; 2014 Mar; 107(3):149-57. PubMed ID: 24630753
[TBL] [Abstract][Full Text] [Related]
10. Eplerenone survival benefits in heart failure patients post-myocardial infarction are independent from its diuretic and potassium-sparing effects. Insights from an EPHESUS (Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study) substudy.
Rossignol P; Ménard J; Fay R; Gustafsson F; Pitt B; Zannad F
J Am Coll Cardiol; 2011 Nov; 58(19):1958-66. PubMed ID: 22032706
[TBL] [Abstract][Full Text] [Related]
11. Eplerenone prevents an increase in serum carboxy-terminal propeptide of procollagen type I after myocardial infarction complicated by left ventricular dysfunction and/or heart failure.
Stienen S; Ferreira JP; Pitt B; Cleland JG; Pellicori P; Girerd N; Rossignol P; Zannad F
Eur J Heart Fail; 2020 May; 22(5):901-903. PubMed ID: 32243646
[No Abstract] [Full Text] [Related]
12. Data-Driven Approach to Identify Subgroups of Heart Failure With Reduced Ejection Fraction Patients With Different Prognoses and Aldosterone Antagonist Response Patterns.
Ferreira JP; Duarte K; McMurray JJV; Pitt B; van Veldhuisen DJ; Vincent J; Ahmad T; Tromp J; Rossignol P; Zannad F
Circ Heart Fail; 2018 Jul; 11(7):e004926. PubMed ID: 29997240
[TBL] [Abstract][Full Text] [Related]
13. A systematic review and economic evaluation of the clinical effectiveness and cost-effectiveness of aldosterone antagonists for postmyocardial infarction heart failure.
McKenna C; Burch J; Suekarran S; Walker S; Bakhai A; Witte K; Harden M; Wright K; Woolacott N; Lorgelly P; Fenwick L; Palmer S
Health Technol Assess; 2010 May; 14(24):1-162. PubMed ID: 20492762
[TBL] [Abstract][Full Text] [Related]
14. Fibrosis and cardiac function in obesity: a randomised controlled trial of aldosterone blockade.
Kosmala W; Przewlocka-Kosmala M; Szczepanik-Osadnik H; Mysiak A; Marwick TH
Heart; 2013 Mar; 99(5):320-6. PubMed ID: 23343682
[TBL] [Abstract][Full Text] [Related]
15. Prognostic relevance of magnesium alterations in patients with a myocardial infarction and left ventricular dysfunction: insights from the EPHESUS trial.
Martens P; Ferreira JP; Vincent J; Abreu P; Busselen M; Mullens W; Tang WHW; Böhm M; Pitt B; Zannad F; Rossignol P
Eur Heart J Acute Cardiovasc Care; 2022 Feb; 11(2):148-159. PubMed ID: 35021200
[TBL] [Abstract][Full Text] [Related]
16. Serum sodium and eplerenone use in patients with a myocardial infarction and left ventricular dysfunction or heart failure: insights from the EPHESUS trial.
Martens P; Ferreira JP; Vincent J; Abreu P; Busselen M; Mullens W; Tang WWH; Böhm M; Pitt B; Zannad F; Rossignol P
Clin Res Cardiol; 2022 Apr; 111(4):380-392. PubMed ID: 33893561
[TBL] [Abstract][Full Text] [Related]
17. Galectin-3 and histological, molecular and biochemical aspects of myocardial fibrosis in heart failure of hypertensive origin.
López B; González A; Querejeta R; Zubillaga E; Larman M; Díez J
Eur J Heart Fail; 2015 Apr; 17(4):385-92. PubMed ID: 25684565
[TBL] [Abstract][Full Text] [Related]
18. Potential spironolactone effects on collagen metabolism biomarkers in patients with uncontrolled blood pressure.
Ferreira JP; Rossignol P; Pizard A; Machu JL; Collier T; Girerd N; Huby AC; Gonzalez A; Diez J; López B; Sattar N; Cleland JG; Sever PS; Zannad F
Heart; 2019 Feb; 105(4):307-314. PubMed ID: 30121630
[TBL] [Abstract][Full Text] [Related]
19. Effect of High Thoracic Sympathetic Nerve Block on Serum Collagen Biomarkers in Patients with Chronic Heart Failure.
Sun G; Liu F; Qu R
Cardiology; 2017; 136(2):102-107. PubMed ID: 27591776
[TBL] [Abstract][Full Text] [Related]
20. The effects of eplerenone on length of stay and total days of heart failure hospitalization after myocardial infarction in patients with left ventricular systolic dysfunction.
Gheorghiade M; Khan S; Blair JE; Harinstein ME; Krum H; Mukherjee R; Pitt B;
Am Heart J; 2009 Sep; 158(3):437-43. PubMed ID: 19699868
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
